About
Immuno-modulatory antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (19)
Aurélien MARABELLE
Aurélien MARABELLE, MD, PhDClinical Director,Cancer Immunotherapy Program,Gustave Roussy, Paris.Director, Translational ResearchLaboratory in Immunotherapy,INSERM.
ImCheck Therapeutics
team_member
Bram VANPARYSPhD
Bram VANPARYSPhD, MBAGimv
ImCheck Therapeutics
team_member
Daniel OLIVE
Daniel OLIVE, MD, PhDHead of the Immunity and Cancer lab, CRCM.Professor of Immunology andDirector of the Oncology Research Programsat Aix Marseille University.Scientific founder of ImCheck.
ImCheck Therapeutics
founder
Jean Jacques FOURNIE
Jean Jacques FOURNIE, PhDResearch Director at CNRS(French National Center forScientific Research) in CancerResearch Center of Toulouse.
ImCheck Therapeutics
team_member
Jeffrey WEBER MD
Jeffrey WEBER MD, PhD- In Memoriam -Deputy Director of thePerlmutter Cancer Center andHead of Experimental Therapeutics.
ImCheck Therapeutics
team_member
Johann de BONO
Johann de BONO, MD, PhDRegius Professor ofCancer Research.Professor of ExperimentalCancer Medicine and HonoraryConsultant in Medical Oncology.
ImCheck Therapeutics
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
348
By Phase
PHASE1/PHASE2: 2
By Status
ACTIVE_NOT_RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05307874Lead Sponsor
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
PHASE1/PHASE2Active, not recruiting
56 participants
Started: Apr 19, 2022 · Completed: Dec 31, 2025
NCT04243499Lead Sponsor
First-in-Human Study of ICT01 in Patients With Advanced Cancer
PHASE1/PHASE2Active, not recruiting
292 participants
Started: Feb 10, 2020 · Completed: Dec 31, 2025
Locations (1)
Headquarters
Marseille, France
Map
Loading map...